Sfoglia per AUTORE
DI BARTOLOMEO M
Collezione AOU San Luigi di Orbassano

  

Items : 11

Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial. in The Lancet. Oncology / Lancet Oncol. 2024 Dec;25(12):1539-1550. doi: 10.1016/S1470-2045(24)00580-1. Epub 2024 Nov 15.

2024
AOU San Luigi di Orbassano

Randon G; Lonardi S; Fassan M; Palermo F; Tamberi S; Giommoni E; Ceccon C; Di Donato S; Fornaro L; Brunetti O; De Vita F; Bittoni A; Chini C; Spallanzani A; Nappo F; Bethaz V; Strippoli A; Latiano T; Cardellino GG; Giuliani F; Morano F; Niger M; Raimondi A; Prisciandaro M; Pircher CC; Sciortino C; Marchesi S; Garattini SK; Airò G; et alii...

Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial. in BMC cancer / BMC Cancer. 2023 Sep 26;23(1):908. doi: 10.1186/s12885-023-11287-2.

2023
AOU San Luigi di Orbassano

Corti F; Brizzi MP; Amoroso V; Giuffrida D; Panzuto F; Campana D; Prinzi N; Milione M; Cascella T; Spreafico C; Randon G; Oldani S; Leporati R; Scotto G; Pulice I; Stocchetti BL; Porcu L; Coppa J; Di Bartolomeo M; de Braud F; Pusceddu S;

Early onset metastatic colorectal cancer in patients receiving panitumumab-based upfront strategy: Overall and sex-specific outcomes in the Valentino trial. in International journal of cancer / Int J Cancer. 2022 Nov 15;151(10):1760-1769. doi: 10.1002/ijc.34156. Epub 2022 Jun 23.

2022
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Morano F; Pietrantonio F; Di Maio M; Di Bartolomeo M; Rossi A; Giordano M; Antonuzzo L; Petrelli F; Ratti M; Berenato R; Clavarezza M; Zaniboni A; Murialdo R; Tampellini M; Fanchini L; Antoniotti C; Bozzarelli S; Sartore-Bianchi A; Lonardi S; Pagani F; Randon G; Prisciandaro M; Raimondi A;

Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors. in JAMA network open / JAMA Netw Open. 2022 Feb 1;5(2):e220290. doi: 10.1001/jamanetworkopen.2022.0290.

2022
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Modica R; Andreasi V; Spada F; Severi S; Bracigliano A; Ambrosio MR; Zanata I; Puliafito I; Lamberti G; Cingarlini S; Rocca PA; Pignata SA; Rinzivillo M; Persano I; Versari A; Bongiovanni A; Lastoria S; Maccauro M; Seregni E; Di Maio M; Porcu L; Giacomelli L; Ricci C; Corti F; Perfetti V; Cirillo F; Grimaldi F; Cives M; Bajetta E; et alii...

Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study. in ESMO open / ESMO Open. 2021 Oct;6(5):100246. doi: 10.1016/j.esmoop.2021.100246. Epub 2021 Aug 17.

2021
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Di Bartolomeo M; Pietrantonio F; Di Maio M; Morano F; Corallo S; Berenato R; Ratti M; Clavarezza M; Zaniboni A; Murialdo R; Tampellini M; Ritorto G; Raimondi A; Fucà G; Leone AG; Lonardi S; Antoniotti C; Smiroldo V; Amatu A;

Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study. in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer / Support Care Cancer. 2021 Jul;29(7):3971-3980. doi: 10.1007/s00520-020-05972-2. Epub 2021 Jan 3.

2021
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

de Braud F; Di Bartolomeo M; Pietrantonio F; Randon G; Prisciandaro M; Ambrosini M; Pagani F; Niger M; Antista M; Longarini R; Cinieri S; Giordano M; Antonuzzo L; Petrelli F; Toscano G; Tomasello G; Zaniboni A; Clavarezza M; Murialdo R; Tampellini M; Racca P; Amatu A; Rimassa L; Antoniotti C; Morano F; Lonardi S; Corallo S; Raimondi A;

Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2021 Feb;144:31-40. doi: 10.1016/j.ejca.2020.11.017. Epub 2020 Dec 13.

2021
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Pietrantonio F; Morano F; Calareso G; Di Bartolomeo M; de Braud F; Vaiani M; Greco FG; Prisciandaro M; Pagani F; Palermo F; Raimondi A; Antista M; Clavarezza M; Racca P; Tomasello G; Murialdo R; Tampellini M; Zaniboni A; Smiroldo V; Antoniotti C; Bergamo F; Rimassa L; Lonardi S; Cremolini C; Randon G; Corallo S; Manca P;

Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2020 Aug;135:230-239. doi: 10.1016/j.ejca.2020.04.048. Epub 2020 Jul 2.

2020
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Pietrantonio F; Di Bartolomeo M; Peverelli G; de Braud F; Antista M; Niger M; Bergamo F; Cinieri S; Longarini R; Giordano M; Antonuzzo L; Petrelli F; Adamo V; Tomasello G; Zaniboni A; Clavarezza M; Murialdo R; Tampellini M; Ritorto G; Sartore-Bianchi A; Rimassa L; Antoniotti C; Corallo S; Lonardi S; Morano F; Raimondi A; Di Maio M; Raimondi A; Di Maio M; et alii...

Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. in JAMA oncology / JAMA Oncol. 2019 Sep 1;5(9):1268-1275. doi: 10.1001/jamaoncol.2019.1467.

2019
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Longarini R; Petrelli F; Giordano M; Tomasello G; Adamo V; Zaniboni A; Murialdo R; Smiroldo V; Niger M; Antista M; Caporale M; Berenato R; Clavarezza M; Racca P; Tampellini M; Sartore-Bianchi A; Bergamo F; Rimassa L; Cremolini C; Raimondi A; Lonardi S; Miceli R; Corallo S; Pietrantonio F; Morano F; Cinieri S; Falcone A; Zagonel V; Di Bartolomeo M; et alii...

Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial. in BMC cancer / BMC Cancer. 2019 Mar 29;19(1):283. doi: 10.1186/s12885-019-5498-3.

2019
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Ciuffreda L; Basso M; Catalano V; Bracarda S; Verusio C; Maiello E; Cinieri S; Giuliani F; Tassinari D; Frassineti GL; Spallanzani A; Bonetti A; Tortora G; Scagliotti G; Pinotti G; Tomasello G; Bertolini A; Zaniboni A; Longarini R; Luporini AG; Rimassa L; Di Costanzo F; Cardellino GG; Scartozzi M; Berardi R; Di Donato S; Lonardi S; Tamberi S; Antista M; et alii...

A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. in Endocrine-related cancer / Endocr Relat Cancer. 2018 Jun;25(6):607-618. doi: 10.1530/ERC-17-0489. Epub 2018 Mar 20.

2018
AOU San Luigi di Orbassano

Pusceddu S; Barretta F; Trama A; Botta L; Milione M; Buzzoni R; De Braud F; Mazzaferro V; Pastorino U; Seregni E; Mariani L; Gatta G; Di Bartolomeo M; Femia D; Prinzi N; Coppa J; Panzuto F; Antonuzzo L; Bajetta E; Brizzi MP; Campana D; Catena L; Comber H; Dwane F; Fazio N; Faggiano A; Giuffrida D; Henau K; Ibrahim T; et alii...